The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial.
Jose Maria Piulats Rodriguez
No relevant relationships to disclose
Maria Ochoa de Olza
No relevant relationships to disclose
Manuel Codes
No relevant relationships to disclose
Jose A. Lopez-Martin
No relevant relationships to disclose
Alfonso Berrocal
No relevant relationships to disclose
Margarita GarcĂ­a
No relevant relationships to disclose
Alfonso Gurpide
No relevant relationships to disclose
Blanca Homet
No relevant relationships to disclose
Salvador Martin-Algarra
No relevant relationships to disclose